On April 20, 2026, Knowledge Ecology International (KEI) submitted comments to the NIH regarding the “Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration” (91 FR 16205) to Perpetual Biosciences, Inc.
The technology involves the use of PEDF peptides for the treatment of retinal degeneration. In our comments, KEI emphasized that the NIH is required under 35 USC 209 to limit the scope of exclusive rights to only what is reasonably necessary, and KEI urged the NIH to include specific safeguards to protect the public interest in both access and affordability.
KEI’s full comments are available here:KEI-Comments-NIH-License-Perpetual-Biosciences-20April2026